舒尼替尼治疗的肾细胞癌患者血管生成标志物的研究
A Study of Angiogenesis Markers in Patients with Renal Cell Carcinoma Undergoing Therapy with Sunitinib.
作者信息
Stubbs Clive, Bardoli Antonio D, Afshar Mehran, Pirrie Sarah, Miscoria Manuela, Wheeley Isabella, Porfiri Emilio
机构信息
University of Birmingham, Birmingham, U.K.
College of Medical and Dental Sciences, University of Birmingham, Birmingham, U.K.
出版信息
Anticancer Res. 2017 Jan;37(1):253-259. doi: 10.21873/anticanres.11315.
BACKGROUND
Sunitinib is a tyrosine kinase inhibitor (TKI) targeting tumour angiogenesis in patients with advanced renal cell carcinoma (RCC). Currently no universally agreed model exists correlating the expression of angiogenesis markers with the success of treatment.
PATIENTS AND METHODS
We retrospectively analysed archival tissue for 59 RCC patients treated with sunitinib. The expression of angiogenesis markers VEGF-A, VEGFR, PDGFββ, PDGFR, CCND1 and CA9 was assessed by immunohistochemistry (IHC) and correlated with overall survival (OS) and progression-free survival (PFS).
RESULTS
The median OS and median PFS of the whole group of patients was 24.6 months (17.3-34.2) and 19.5 months (11-27) respectively. VEGFA was positive in 29% of tumors, whereas VEGFR was expressed in only 12% of tumours. PDGFββ and its receptor were detected in a minority of cases. CCND1 and CA9 were positive in 44% and 60% of cases.
CONCLUSION
The OS and PFS achieved by our patients reflected previous observations seen with sunitinib, but no correlation was found between expression of angiogenesis markers and clinical outcome.
背景
舒尼替尼是一种酪氨酸激酶抑制剂（TKI），用于治疗晚期肾细胞癌（RCC）患者的肿瘤血管生成。目前尚无普遍认可的模型将血管生成标志物的表达与治疗成功相关联。
患者与方法
我们回顾性分析了59例接受舒尼替尼治疗的RCC患者的存档组织。通过免疫组织化学（IHC）评估血管生成标志物VEGF-A、VEGFR、PDGFββ、PDGFR、CCND1和CA9的表达，并与总生存期（OS）和无进展生存期（PFS）相关联。
结果
全组患者的中位OS和中位PFS分别为24.6个月（17.3 - 34.2）和19.5个月（11 - 27）。29%的肿瘤中VEGFA呈阳性，而只有12%的肿瘤表达VEGFR。少数病例中检测到PDGFββ及其受体。44%和60%的病例中CCND1和CA9呈阳性。
结论
我们患者的OS和PFS反映了先前使用舒尼替尼时观察到的情况，但未发现血管生成标志物的表达与临床结果之间存在相关性。
Zotero 插件